SISVEL-INTERNATIONAL
14.4.2020 14:27:08 CEST | Business Wire | Press release
Sisvel International S.A. (“Sisvel”) announced today the launch of its “MIOTY” Licensing Platform, a new joint patent licensing effort for the MIOTY technology. The platform has been launched with patents owned, or controlled by, Fraunhofer-Institute for Integrated Circuits IIS (“Fraunhofer IIS”) and Diehl Metering GmbH (“Diehl”).
Fraunhofer IIS and Diehl are working together under the brand name MIOTY in the area of wireless technology for low power wide area networks (“LPWAN”). MIOTY technology is based on the protocol family Telegram Splitting Ultra Narrow band (“TS-UNB”) of the ETSI standard TS 103 357 (“TS-UNB Specification”).
Sisvel is organizing this licensing platform to make MIOTY technology accessible on fair, reasonable, and non-discriminatory terms and conditions by offering a royalty-bearing, non-transferable, non-assignable, non-exclusive license, with no right to grant sublicenses, under patents essential to the TS-UNB Specification. In addition, Sisvel offers a license to patents complementary to MIOTY implementations.
Further information about the terms and conditions of Sisvel’s MIOTY licenses are available on Sisvel’s website https://www.sisvel.com/licensing-programs/wireless-communications/mioty/introduction
. For more details you may contact Sisvel at the following e-mail address MIOTY@sisvel.com
.
The MIOTY Licensing Platform remains open to additional patent owners with relevant patents. Thus, Sisvel invites all parties that have patents or patent applications they believe to be essential to the protocol family TS-UNB of the ETSI standard TS 103 357 to contact Sisvel and submit those patent(s) for an evaluation by the program’s designated, independent evaluators.
About Fraunhofer IIS
The Fraunhofer-Gesellschaft is the leading organization for applied research in Europe. Its research activities are conducted by 74 institutes and research units at locations throughout Germany. The Fraunhofer-Gesellschaft employs a staff of more than 28,000, who work with an annual re-search budget totaling more than 2.8 billion euros.
The Fraunhofer Institute for Integrated Circuits IIS is one of the world’s leading application-oriented research institutions for microelectronic and IT system solutions and services. It is the largest of all Fraunhofer Institutes. Research at Fraunhofer IIS revolves around two guiding topics:
In the area of “Audio and Media Technologies”, the institute has been shaping the digitalization of media for more than 30 years now. Fraunhofer IIS was instrumental in the development of mp3 and AAC and played a significant role in the digitalization of the cinema. Current developments are opening up whole new sound worlds and are being used in virtual reality, automotive sound systems, mobile telephony, streaming and broadcasting.
In the context of “cognitive sensor technologies”, the institute researches technologies for sensor technology, data transmission technology, data analysis methods and the exploitation of data as part of data-driven services and their accompanying business models. This adds a cognitive component to the function of the conventional “smart” sensor.
Nearly 1,100 employees conduct contract research for industry, the service sector and public authorities. Founded in 1985 in Erlangen, Fraunhofer IIS has now 15 locations in 11 cities: Erlangen (headquarters),
Nuremberg, Fürth, Dresden, further in Bamberg, Waischenfeld, Coburg, Würzburg, Ilmenau, Deggendorf and Passau. The budget of 170 million euros is mainly financed by projects. 26 percent of the budget is subsidized by federal and state funds.
Detailed information on: www.iis.fraunhofer.de/en
About Diehl Metering
Diehl Metering is a corporate division of the Diehl Group, headquartered in Nuremberg. With a total annual turnover of 3.75 billion euros, the technology company employs around 17,200 people worldwide. The corporate division Metering supplies solutions for the intelligent use of water, thermal energy, gas and electricity.
Diehl Metering provides smart metering solutions to utilities companies through the intelligent networking of various metering devices into larger data platforms. These solutions offer transparency for utilities and municipalities, and enable considerably increased efficiency in reading, billing and service processes. Diehl Metering’s customers are also able to benefit from real-time effects such as early recognition of leaks and the optimisation of distribution networks through intelligent information regarding prompt adjustment of the offer to suit actual needs.
With Diehl Metering utilities are already perfectly equipped for smart metering as an important component of smart city concepts. Thanks to more than 20 years of experience with the company’s own radio technology, Diehl Metering has at its disposal excellent expertise in communications within the Internet of Things. The MIOTY LPWAN technology has been developed jointly by Fraunhofer IIS and Diehl Metering.
For further information, please visit www.diehl.com/metering
About Sisvel
Sisvel is a world leader in fostering innovation and managing intellectual property. The Group identifies, evaluates and maximizes the value of IP assets for its partners around the world, providing firms with a revenue stream which can be reinvested in innovation for the generation of future revenues. Founded in 1982, the Group is headquartered in Luxembourg and has subsidiaries in China, Germany, Italy, Japan, Spain, the United States and the United Kingdom. The Group has a long history of managing successful patent portfolios including those related to the audio compression standards known as MP3 and MPEG Audio, as well as broadcasting and receiving of digital terrestrial television standards maintained by the DVB Project. Sisvel currently operates patent pools and joint licensing programs in the fields of mobile communication; wireless local area networking 802.11; digital video broadcasting; recommendation engine and broadband access to data networks.
For additional information, please visit: www.sisvel.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200414005501/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
